Evropská unie - čeština - EMA (European Medicines Agency)

novartis europharm limited  - indacaterol acetate, mometasone furoate - astma - léky na obstrukční onemocnění dýchacích cest, - atectura breezhaler is indicated as a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.

Evropská unie - čeština - EMA (European Medicines Agency)

accord healthcare s.l.u. - rivaroxaban - acute coronary syndrome; coronary artery disease; peripheral arterial disease; venous thromboembolism; stroke; atrial fibrillation; pulmonary embolism - antitrombotické činidla - prevence žilní tromboembolie (vte) u dospělých pacientů, kteří podstoupili elektivní operaci náhrady kyčelního nebo kolenního kloubu. léčba hluboké žilní trombózy (dvt) a plicní embolie (pe) a prevence rekurentní dvt a pe u dospělých. (see section 4. 4 for haemodynamically unstable pe patients. léčba hluboké žilní trombózy (dvt) a plicní embolie (pe) a prevence rekurentní dvt a pe u dospělých. (see section 4. 4 pro hemodynamicky nestabilní pe pacientů). adultsprevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. léčba hluboké žilní trombózy (dvt) a plicní embolie (pe) a prevence rekurentní dvt a pe u dospělých. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. rivaroxaban accord, co administered with acetylsalicylic acid (asa) alone or with asa plus ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers (see sections 4. 3, 4. 4 a 5. rivaroxaban accord, co administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. léčba hluboké žilní trombózy (dvt) a plicní embolie (pe) a prevence rekurentní dvt a pe u dospělých. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Evropská unie - čeština - EMA (European Medicines Agency)

janssen-cilag international n.v.    - ponesimod - roztroušená skleróza, relaps-remitentní - imunosupresiva - ponvory is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features.

Evropská unie - čeština - EMA (European Medicines Agency)

vetcare oy - medetomidine hydrochloride, vatinoxan hydrochloride - psycholeptika, hypnotika a sedativa - psi - to provide restraint, sedation and analgesia during conduct of non-invasive, non-painful or mildly painful procedures and examinations intended to last no more than 30 minutes.

Česká republika - čeština - Adama

adama - rozpustný koncentrát - smáčedla

Evropská unie - čeština - EMA (European Medicines Agency)

les laboratoires servier - ivosidenib - leukemia, myeloid, acute; cholangiocarcinoma - antineoplastická činidla - tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) with an isocitrate dehydrogenase-1 (idh1) r132 mutation who are not eligible to receive standard induction chemotherapy (see section 5. tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an idh1 r132 mutation who were previously treated by at least one prior line of systemic therapy.

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

herbacos recordati s.r.o., pardubice array - 12 kyselina acetylsalicylovÁ; 1064 paracetamol; 223 kofein - tableta - 250mg/200mg/50mg - paracetamol, kombinace kromĚ psycholeptik

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

dr. max pharma s.r.o., praha array - 12 kyselina acetylsalicylovÁ - tableta - 500mg - kyselina acetylsalicylovÁ

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

patheon softgels b.v., tilburg array - 1593 ibuprofen - měkká tobolka - 400mg - ibuprofen

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

bayer s.r.o., praha array - 12 kyselina acetylsalicylovÁ - obalená tableta - 500mg - kyselina acetylsalicylovÁ